Ethics of Cell and Gene Therapy (ECGT) Committee

Charter

The ISCT Committee on the Ethics of Cell and Gene Therapy (ECGT) strives to:

1. Identify key ethical issues associated with the development, regulatory authorization, marketing, and distribution of cell and gene therapies.
2. Share knowledge and effective strategies among scientific and medical societies, health care providers and institutions, patient associations, and patients and their families.
3. Promote rigorous research, appropriate clinical investigation and application of, and equitable access to cell- and gene-based therapies.

Formerly known as the ISCT Presidential Task Force on the Use of Unproven and/or Unethical Cell and Gene Therapies (PTF).

Featured Resource

• Unproven Cell & Gene Therapies: Guidelines and Resources for Healthcare Providers
  

Selected Publications

• International Society for Cell & Gene Therapy Expanded Access Working Group position paper: key considerations to support equitable and ethical expanded access to investigational cell- and gene-based interventions (2025)
  
  
• An International Society for Cell & Gene Therapy working group short report on the future of expanded access to unapproved cell and gene therapies (2023)
  
  
• International Society for Cell & Gene Therapy Position Paper: Key considerations to support evidence-based cell and gene therapies and oppose marketing of unproven products (2023)
  
  
• The peril of the promise of speculative cell banking: Statement from the ISCT Committee on the Ethics of Cell and Gene Therapy (2022)
  
  
• Patient access to and ethical considerations of the application of the European Union hospital exemption rule for advanced therapy medicinal products (2022)
  
  

Committee Chair

Bruce Levine PhD University of Pennsylvania School of Medicine United States

Committee Vice Chairs

Members